Methylation in the Promoters of HS3ST2 and CCNA1 Genes is Associated with Cervical Cancer in Uygur Women in Xinjiang. Issue 4 (October 2014)

• Record Type: Journal Article
• Authors: Zuo, Qiangqiang; Zheng, Weinan; Zhang, Jinli; Pan, Zemin; Liu, Yinyin; Long, Haichen; Fan, Peiwen; Guo, Caili; Li, Feng; Shao, Renfu
• Is Part Of: International journal of biological markers. Volume 29:Issue 4(2014)
• Page Start: 354
• Page End: 362
• Publication Date: 2014-10
• Subjects: Cervical cancer -- CIN -- Gene methylation -- HPV; Cell receptors -- Periodicals; Histochemistry -- Periodicals; Tumor markers -- Periodicals; Tumor antigens -- Periodicals; 616.99407582
• DOI: 10.5301/jbm.5000107
• Languages: English
• ISSNs: 0393-6155

Abstract

: We assessed the suitability of HS3ST2 and CCNA1 genes as biomarkers for the early detection of cervical cancer in Uygur women in Xinjiang, China. Methylation-specific PCR (MSP) and HPV (HPV16 and HPV18)–specific PCR were performed on 110 cervical samples: 40 normal cervices, 10 cervical intraepithelial neoplasia 1 (CIN1), 10 CIN2, 10 CIN3 and 40 cervical cancer tissues. The expression of the 2 genes was measured by reverse transcription PCR (RT-PCR) in 10 methylation-positive and 10 methylation-negative cervical tissues. We found that both HS3ST2 and CCNA1 genes were methylated in 38 of the 40 cervical cancer tissues, 9 of the 10 CIN3, and 6 of the 10 CIN2. In contrast, methylation of these 2 genes was found in only 1 of the 40 normal tissues and none of 10 CIN1. Furthermore, hypermethylated HS3ST2 and CCNA1 genes were correlated with infection with HPV16 and HPV18 in high-grade squamous intraepithelial lesions (HSILs) and cervical cancer (both p<0.05). The expression of HS3ST2 and CCNA1 genes was lower in the methylation-positive cervical tissues than in the methylation-negative cervical tissues. Our results indicate that HS3ST2 and CCNA1 genes may play important roles in HPV-induced cervical cancer and that patients with specific hypermethylated genes may have a greater risk of progressing to invasive cervical cancer.